Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031347 | 0.93 | KMT2A (0.33) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL13031326 | 0.93 | KCNH2 (0.36) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL13031362 | 0.89 | KMT2A (0.33) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL3591188 | 0.85 | CPT1A (0.34) | KCNH2HPGD | |
| SCHEMBL13031179 | 0.85 | IRAK4 (0.33) | SMN1; SMN2PTGS2PTGS1KCNH2GRIN2B | |
| SCHEMBL13031372 | 0.85 | PTGS2 (0.35) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL13072300 | 0.84 | KMT2A (0.34) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL13031205 | 0.84 | GRIN2B (0.35) | SMN1; SMN2NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL13031479 | 0.83 | NAMPT (0.36) | PTGS2PTGS1KCNH2GRIN2BGRIN1 | |
| SCHEMBL13031370 | 0.83 | PTGS2 (0.35) | PTGS2PTGS1KCNH2GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | SMN1; SMN2 4711/4885NPC1 1365/4885RAB9A 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.